07:00 , Jun 6, 2016 |  BioCentury  |  Finance

Rushing to America

Biotechs in the U.S. are seeing a surge of interest from Chinese investors that reflects myriad motives. These range from a desire to access assets to serve a domestic market that is hungry for innovative...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Amicus Therapeutics, Callidus Biopharma, GlaxoSmithKline deal

Amicus announced two deals and a headcount reduction, positioning itself to fund an enzyme replacement pipeline through 2015. Amicus reacquired rights to migalastat, its Fabry's disease therapy, from partner GlaxoSmithKline. Under a July 2012 amendment...
08:00 , Nov 25, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €4 (21%) to €15 on Friday after EMA's CHMP issued a negative opinion recommending against approval of an MAA for Masican masitinib to treat gastrointestinal stromal tumors (GIST)...
00:55 , Nov 21, 2013 |  BC Extra  |  Company News

Amicus reacquires migalastat rights, acquires Callidus

Amicus Therapeutics Inc. (NASDAQ:FOLD) announced two deals, a financing and a headcount reduction Wednesday, positioning itself to fund an enzyme replacement pipeline through 2015. Amicus reacquired rights to migalastat, its Fabry's disease therapy, from partner...
07:00 , Sep 30, 2013 |  BioCentury  |  Emerging Company Profile

Callidus: Chemical conjugation

Callidus Biopharma Inc . is developing a compound for Pompe's disease that links a therapeutic enzyme with a targeting peptide that could lead to more efficient delivery to diseased tissue and therefore require lower doses...
07:00 , May 20, 2013 |  BC Week In Review  |  Financial News

Callidus Biopharma completes venture financing

Callidus Biopharma Inc. , Doylestown, Pa.   Business: Endocrine/Metabolic   Date completed: 5/14/13   Type: Venture financing   Raised: $4.6 million  ...
00:39 , May 15, 2013 |  BC Extra  |  Financial News

Callidus raises $4.6M in series A

Callidus Biopharma Inc. (Doylestown, Pa.) debuted on Tuesday with $4.6 million in a series A round led by two undisclosed investors, with participation from undisclosed private investors. Callidus is attaching insulin-like growth factor 2 (...